Foundation Medicine and Ariad Pharmaceuticals forged a genomic profiling collaboration to study AP26113, Ariad’s investigational dual-inhibitor of ALK and EGFR in patients with non-small-cell lung cancer (NSCLC) and other cancers. Foundation Medicine will work with Ariad to generate genomic profile information for patients enrolled in Ariad’s ongoing Phase I/II trial, and these data will be matched with clinical observations to understand the activity and selectivity profile of AP26113.
“It is important that we have a deep molecular understanding of patients’ tumors as they begin treatment with AP26113, especially those patients with complex prior treatment histories,” stated Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer at Ariad. “Foundation Medicine is at the forefront of genomic profiling technologies that will provide molecular insights on a wide array of clinically relevant tumor genes including ALK and EGFR alteration status. We look forward to collaborating on the AP26113 program as we move into anticipated pivotal trial(s) in 2013.”
Just yesterday, AstraZeneca announced that they will be using Foundation Medicine’s molecular information platform FoundationOne™ to identify alterations in tumor genes that may predict a person’s response or resistance to targeted cancer therapies. Foundation Medicine entered similar collaborations with Sanofi and Novartis earlier this year.